Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Myeloproliferative Disorders 2Leukemia, Myelomonocytic, Chronic 2Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Esophageal Neoplasms 1

Interventions

Rituximab 165Cyclophosphamide 163fludarabine phosphate 95Peripheral Blood Stem Cell Transplantation 88Filgrastim 72Etoposide 65Mycophenolic Acid 63Whole-Body Irradiation 62Cytarabine 59Cyclosporine 53Melphalan 52Tacrolimus 47Busulfan 43Radiotherapy 42Lenalidomide 42Bortezomib 40ibrutinib 39fludarabine 39Methotrexate 38Antilymphocyte Serum 38Carmustine 37Bendamustine Hydrochloride 35Vincristine 33Doxorubicin 32Dexamethasone 32Granulocyte Colony-Stimulating Factor 29Prednisone 26Cord Blood Stem Cell Transplantation 25venetoclax 22obinutuzumab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Mantle-Cell × eprenetapopt × Clear all
NCT04990778 2022-03-10

Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡